Limitations

This study aimed at implementing the pharmaceutical care on the HD patients of hospitals from the teaching, government and private sectors to assess the impact of pharmaceutical care in the HRQoL, economic and clinical outcomes. In this study, patients were followed up to 12 months. So the long-term humanistic and clinical outcomes of the patients were not collected. This study aimed at collecting the out-of-pocket expenses of out-patient HD patients. The other perspectives like the payers, providers, and societal perspectives were not able to calculate due to difficulty in getting the indirect costs. As this study is limited to out-patient HD patients the in-patient costs of the patients were not calculated. The pharmacoeconomic sensitivity analysis was not conducted due to the limited resources. The study was unable to assess the other clinical outcome like calcium, phosphorous, parathyroid hormone, potassium and iron levels due to high cost of the laboratory tests.